Akèy › Kansè Poumon ki pa ti selil › Montana
Etid klinik pou Kansè Poumon ki pa ti selil nan Montana
18 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan Montana.
Vil nan Montana
Tèks ofisyèl etid la (Anglè)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Community Hospital of Anaconda, Anaconda
- Billings Clinic Cancer Center, Billings
- Bozeman Health Deaconess Hospital, Bozeman
- ak 3 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04267848A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Billings Clinic ( Site 3255), Billings
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07513376Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Billings Clinic Cancer Center, Billings
- Bozeman Health Deaconess Hospital, Bozeman
- Benefis Sletten Cancer Institute, Great Falls
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT07388524Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Community Hospital of Anaconda, Anaconda
- Billings Clinic Cancer Center, Billings
- Saint Vincent Frontier Cancer Center, Billings
- ak 4 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06498635Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- St. Vincent Frontier Cancer Center, Billings
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06881784A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana, Billings
- Bozeman Health Deaconess Hospital - Bozeman Health Cancer Center, Bozeman
- Bozeman Health Deaconess Hospital - Bozeman Health Clinical Research, Bozeman
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07144280This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- SCL Health - Montana, Billings
- SCL Health - Montana, Billings
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06758401Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Community Hospital of Anaconda, Anaconda
- Billings Clinic Cancer Center, Billings
- Bozeman Health Deaconess Hospital, Bozeman
- ak 6 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT03191149Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Logan Health Research, Kalispell
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06899126A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- St. Vincent Frontier Cancer Center-Research ( Site 0105), Billings
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06345729Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
- St. Vincent Frontier Cancer Center, Billings
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT07288177Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- Intermountain Health - St. Vincent Frontier Cancer Center, Billings
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 30, 2026 · NCT06162221Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Community Hospital of Anaconda, Anaconda
- Billings Clinic Cancer Center, Billings
- Bozeman Health Deaconess Hospital, Bozeman
- ak 3 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 3, 2026 · NCT05642572Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- Community Hospital of Anaconda, Anaconda
- Billings Clinic Cancer Center, Billings
- Bozeman Health Deaconess Hospital, Bozeman
- ak 3 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT06116682Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Community Hospital of Anaconda, Anaconda
- Billings Clinic Cancer Center, Billings
- Bozeman Health Deaconess Hospital, Bozeman
- ak 3 plis
Ap rekriteFaz 2
18 Minutes · Tout sèks · Mizajou May 5, 2026 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Community Hospital of Anaconda, Anaconda
- Billings Clinic Cancer Center, Billings
- Bozeman Health Deaconess Hospital, Bozeman
- ak 3 plis
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou May 5, 2026 · NCT06616584Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Community Hospital of Anaconda, Anaconda
- Billings Clinic Cancer Center, Billings
- Montana Cancer Consortium NCORP, Billings
- ak 5 plis
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 17, 2026 · NCT06418204SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Billings
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.